Evidence map›Paper›PMID 33771286›Full record

ArticleJournal of substance abuse treatment2021

Long-term functioning to provide empirical support for the clinical relevance of treatment outcomes for methamphetamine use disorders.

André Q C Miguel, Crystal L Smith, Ekaterina Burduli, John M Roll, Sterling McPherson

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of substance abuse treatment, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

André Q C MiguelElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL) and the Program of Excellence in Addiction Research, Washington State University, Spokane, WA, United States; Department of Psychiatry, Federal University of Sao Paulo, Sao Paulo, Brazil. Electronic address: andre.miguel@wsu.edu.
Crystal L SmithElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL) and the Program of Excellence in Addiction Research, Washington State University, Spokane, WA, United States.
Ekaterina BurduliElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States.
John M RollElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL) and the Program of Excellence in Addiction Research, Washington State University, Spokane, WA, United States.
Sterling McPhersonElson S. Floyd College of Medicine, Washington State University, Spokane, WA, United States; Analytics and PsychoPharmacology Laboratory (APPL) and the Program of Excellence in Addiction Research, Washington State University, Spokane, WA, United States.
Georgia Highlands College · USWashington State University Spokane · US

Funding

Behavior Change: Reinforcemnt Schedule EffectsR01DA017407 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI ROLL, JOHN M. · 2003 to 2006
$1.1M
Contingency Management: Duration EffectsR01DA017084 · NIDA · FRIENDS RESEARCH INSTITUTE, INC. · PI ROLL, JOHN M. · 2004 to 2007
$997k
NIDA NIH HHS R01 DA017084NIDA NIH HHS R01 DA017407
6 · The paper itself

Abstract

backgroundResearch has yet to empirically evaluate methamphetamine (MA) use outcome measures commonly used to indicate treatment success. Clinically meaningful outcomes must be associated with long-term functioning in important life domains. This study evaluated the association between different MA use outcomes and long-term life-functioning.

methodThe data that this study used in its secondary analyses were pooled from two treatment trials for MA use disorders (n = 237). The study conducted multiple regression analyses (with multiple imputation for missing data) to determine the association of six within-treatment MA use outcome measures with problem severity in seven life domains and a proxy measure for overall functioning, measured with the Addiction Severity Index (ASI) and assessed at an 8-month follow-up.

resultsThe longest duration of abstinence (LDA) outcome achieved the most consistent performance, being associated with better scores in five of eight ASI outcomes (β ranging from -0.203 to -0.291; p < .01). The complete abstinence during treatment demonstrated the poorest performance and was not significantly associated with any of the ASI outcomes. All other MA use outcome measures were significantly (p < .01) associated with at least one ASI outcome.

conclusionThis study provides empirical support for the use of LDA as a clinically relevant indicator of treatment success for MA use disorders, while also indicating the limitations of using complete abstinence during treatment to determine treatment success. Based on these findings, providers and researchers should use LDA as a primary outcome for MA use disorder treatments and trials.

Indexed as

MethamphetamineHumansOutcome Assessment, Health CareTime FactorsTreatment OutcomeMethamphetamineAddiction Severity IndexLong-term functioningOutcome measuresRandomized clinical trialSubstance use disorder

Identifiers

PMID33771286
PMCPMC8004555
OpenAlexW3119695452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.